ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) will host a conference call on November 8, 2022 at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide updates.

The call will be accessible via registration, and details will be available on the ADC Therapeutics investor website. The company specializes in antibody drug conjugates (ADCs) for cancer treatment, with its approved product, ZYNLONTA^®, currently aiding patients with relapsed or refractory lymphoma.

Positive

• ADC Therapeutics is advancing its proprietary PBD-based ADC technology for cancer treatment.
• ZYNLONTA is FDA-approved and currently aids patients with specific lymphoma cases.

Negative

• None.

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m. ET to report financial results for the third quarter 2022 and provide business updates.

To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA^® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005170/en/

Investors

Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

+44 7879 627205

Amanda Loshbaugh

ADC Therapeutics

Amanda.Loshbaugh@adctherapeutics.com

+1 917-288-7023

Media

Mary Ann Ondish

ADC Therapeutics

maryann.ondish@adctherapeutics.com

+1 914-552-4625

Source: ADC Therapeutics SA

FAQ

When will ADC Therapeutics announce its third quarter 2022 financial results?

ADC Therapeutics will announce its third quarter 2022 financial results on November 8, 2022.

How can I access the ADC Therapeutics conference call?

You can access the ADC Therapeutics conference call by registering on their website.

What is ZYNLONTA and its significance for ADC Therapeutics?

ZYNLONTA is ADC Therapeutics' FDA-approved drug for treating relapsed or refractory diffuse large B-cell lymphoma.

Where is ADC Therapeutics located?

ADC Therapeutics is based in Lausanne, Switzerland, with operations in London, San Francisco, and New Jersey.